In concordance with the results of in vitro experiments, in vivo assessment indicated that downregulation of FBLN2 inhibited tumor growth in the mice model, which further verified the oncogenic role of FBLN2 in HCC. The gene discussed is FBLN2; the disease is neoplasm.